Genetic, molecular biology and gene therapy

Genetic, molecular biology and gene therapy

  • Molecular pharmacology and experimental therapies

    Molecular pharmacology and experimental therapies

    Coordinator: Marçal Pastor-Anglada

    Our research group is studying diverse aspects of the cellular and molecular biology of membrane transporters, essentially in epithelial cells and in cells of the immune system. Two of the transporter gene families currently under study are CNT and ENT transporters responsible for the uptake of natural nucleosides and a wide range of drugs used in the treatment of cardiovascular diseases and antitumor therapies and antivirals.

    Read more
  • Human molecular genetics I

    Human molecular genetics I

    Coordinator: Roser Gonzàlez

    This group concerns monogenic disorders associated to different degrees of genetic heterogeneity, from those of lysosomal origin to retinitis pigmentosa. Our first aim was to identify new candidate genes, disease-causing mutations and to analyse the structural and functional features of the mutant alleles. As a continuation of our work, we aim to perform functional studies at the cellular and tissular level, the construction of animal models and new strategies for diagnosis and therapy

    Read more
  • Human molecular genetics II

    Human molecular genetics II

    Coordinator: Daniel Grinberg

    The research of this group includes the study of complex genetic diseases. Studies are currently being made of association with various pathologies using gene markers and candidate loci in order to identify genetic risk factors and to determine the molecular basis of their contribution to pathology.

    We investigate: Lysosomal Diseases,  Costello Syndrome, Retinitis pigmentosa, Homocystinurias, Multiple Osteochondromatosis, Osteoporosis, Migraines, Autism, Attention Deficit Hyperactivity Disorder, Opitz C Syndrome

    Read more
  • Intestinal microbiota

    Intestinal microbiota

    Coordinator: Laura Baldomà

    Our research group has as objective the study of several phenomena related to the communication or dialogue between the microbiota and the intestinal epithelium. The study is framed within a very current theme that tries to elucidate the complex interactions between the host and the bacterium, as well as its association with pathophysiological phenotypes. The relevant implication of the microbiota in health and disease suggests that the modulation of its composition by different means may constitute a new therapeutic approach

    Read more
  • Pharmacological targets in inflammation and metabolic diseases

    Pharmacological targets in inflammation and metabolic diseases

    Coordinator: Manuel Vázquez

    Activation of PPARdelta has been proposed as a therapeutic target to prevent metabolic diseases with an inflammatory basis, such as insulin resistance and type 2 diabetes mellitus. However, the putative molecular mechanisms by which PPARdelta activation might be used to prevent or treat these pathologies remain to be established. We thus aim to examine the effects of PPARdelta activators on hyperinsulinemia and inflammation caused by enhanced plasma free fatty acids, cytokines or advanced glycation endproducts in cellular and animal models of insulin resistance. In addition, we are interested in the link between hyperinsulinemia, inflammation and Alzhimer's disease and the potential role of PPARdelta.

    Read more